US 12,304,883 B2
1,3-fatty diol compounds and derivatives thereof
Haibo Wang, San Pablo, CA (US); and Risha Lindig Bond, South San Francisco, CA (US)
Assigned to Genomatica, Inc., San Diego, CA (US)
Filed by Genomatica, Inc., San Diego, CA (US)
Filed on Oct. 5, 2021, as Appl. No. 17/494,303.
Application 17/494,303 is a continuation of application No. 16/739,645, filed on Jan. 10, 2020, granted, now 11,168,049.
Application 16/739,645 is a continuation of application No. 15/705,012, filed on Sep. 14, 2017, granted, now 10,570,074, issued on Feb. 25, 2020.
Claims priority of provisional application 62/394,537, filed on Sep. 14, 2016.
Prior Publication US 2022/0098133 A1, Mar. 31, 2022
Int. Cl. C07C 33/035 (2006.01); C07H 15/10 (2006.01)
CPC C07C 33/035 (2013.01) [C07H 15/10 (2013.01)] 20 Claims
 
1. A compound having a structure according to Formula VI

OG Complex Work Unit Chemistry
a stereoisomer thereof, or a pharmaceutical salt thereof, wherein
R3 and R4 are independently selected from the group consisting of H, a monosaccharide,
a disaccharide, a trisaccharide, and a polysaccharide, wherein each of the monosaccharide, disaccharide, trisaccharide or polysaccharide is bound via an anomeric carbon to the oxygen at C-1 and/or C-3 in Formula VI;
m is zero, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18;
a chiral center exists at C-3; and
the chiral center at C-3 has an R configuration or an S configuration; and
R3 and R4 are not both H.